ATACOR MEDICAL CLOSES $28M SERIES C FINANCING TO DELIVER NEXT GENERATION EXTRAVASCULAR ICD AND PACING OPTIONS FOR CARDIAC RHYTHM MANAGEMENT
Summary
ATACOR MEDICAL CLOSES $28M SERIES C FINANCING TO DELIVER NEXT GENERATION EXTRAVASCULAR ICD AND PACING OPTIONS FOR CARDIAC RHYTHM MANAGEMENTSAN CLEMENTE, Calif., April 24, 2024-- AtaCor Medical Inc., a privately-held medical device company delivering the next generation of extravascular leads to advance the care of cardiac rhythm management (CRM) patients, announced today that it has completed a $28M Series C financing round. "Arboretum Ventures is thrilled to lead this round and collaborate with the world class team at AtaCor in their efforts to deliver pioneering EV cardiac rhythm management solutions. "As we plan for our upcoming clinical and regulatory milestones, this investment supports efforts that will bring AtaCors novel products to patients." AtaCors EV-ICD and temporary pacing systems have been evaluated in several clinical studies and are designed to offer an important alternative treatment option for patients requiring bradycardia and implantable defibrillation therapies. "Producing safe, effective, and readily deliverable EV ICD and pacing options continues to address a significant unmet need, and we are confident about AtaCors promise to deliver novel solutions in this space."